Reality checks archive
Every hot take, fact-checked.
133 articlesseparating internet hype from what the evidence actually shows. Filter by category, sort by what’s newest, see the evidence tier on every card.
MOTS-c Is on the WADA Banned List. The Human Data Isn't.
USADA this fall classified the mitochondrial exercise-mimetic peptide as prohibited in sport — ahead of any completed randomized controlled trial.
Liraglutide Just Went Generic. The Price Is $226 Now. The Receipts Are Interesting.
Generic liraglutide landed in U.S. pharmacies in 2025 — and by September 2026, it costs $226 while semaglutide commands $1,300.
RFK Jr. Said Ipamorelin Was Coming Back. His Own FDA Panel Already Said No.
RFK Jr. championed ipamorelin on Joe Rogan in February 2026. His own FDA advisory panel had already voted against it in October 2024.
BPC-157 Just Won an FDA Panel Vote. Here's the Part That Got Buried.
An FDA panel voted yes on BPC-157 this summer — tied to a gut indication, not the recovery claims driving 73,000 monthly searches.
Semaglutide Is a Pill Now. Nine Months of Real-World Switching Data Drops at EASD This Week.
The world's biggest diabetes conference opens Monday in Milan — and Novo Nordisk is presenting the first real-world data on whether patients who switched from injections to the oral Wegovy pill held their results.
Thymosin Beta-4 Is Having a Moment. The Clinical Trials Are About Hearts, Not Tendons.
The peptide behind TB-500's recovery marketing is in cardiac trials right now — and recovery is its least-studied application.
GHK-Cu Went From Skincare to Injections. The Doctor Who Studies It Said: 'I Wouldn't Do That to Myself.'
An NPR report published this month documented the copper peptide's leap from anti-aging serums to self-injection — and the researchers behind the animal studies are not following.
Scientists Won the 2026 Lasker for Discovering Orexin. A Drug Built on Their Work Won FDA Approval Last Month. Here’s What You Actually Have in Your Brain.
The 2026 Lasker Award and the first FDA-approved orexin drug trace back to the same neuropeptide — one your lateral hypothalamus has been making since birth.
Tesamorelin Is the Only GH-Axis Peptide the FDA Didn't Ban. Here's Why That's More Complicated Than It Sounds.
Search volume hit 135,000 this month. The approved label covers a much narrower slice of that audience than most people reading it realize.
Retatrutide Just Posted 20% Weight Loss in Phase 3. Here's What It Actually Means.
TRIUMPH-2 results released today show 20.8% body weight loss at 80 weeks — the strongest Phase 3 number yet from the GLP-1 successor race.
CGRP Is the Migraine Molecule Behind 8 FDA Drugs. This Week, Neurologists Said: Prescribe Them First.
The AHS just updated migraine prevention guidelines — and the endogenous neuropeptide behind every CGRP drug has been in your brain since birth.
GLP-1 Is Everywhere. The Endogenous Peptide Behind It All Is Not.
Eli Lilly's oral GLP-1 pill cleared FDA in April. The gut hormone it mimics has been in your body since birth. Here's what the drug companies actually figured out — and what the internet keeps getting wrong.
Zepbound Is Working. Some Users Say It's Also Switched Off Their Joy.
A July 2026 case series in Obesity Pillars documented anhedonia-like symptoms in tirzepatide patients at high doses — and the mechanism points to dopamine.
IGF-1 LR3 Is All Over Fitness TikTok This Month. The Human Trials Are Not.
The modified growth factor peptide trending in bodybuilding creator content this September has a WADA ban, a plausible mechanism, and no human trial record.
Congress Just Introduced the INSULIN Act. The Peptide Is 103 Years Old.
A bipartisan House bill introduced this September wants to cap insulin at $35 — revisiting the economics of a 103-year-old peptide drug.
The GIP Receptor in Tirzepatide Is Having a Moment. The Brain Studies Are Why.
Two August 2026 papers linked GIP receptor signaling to brain neuroprotection — arriving just as semaglutide's Alzheimer's trial came up empty.
Amycretin Just Posted 14.6% Weight Loss at ADA. The Drug Is Two Mechanisms in One Molecule.
The first unimolecular GLP-1/amylin agonist from Novo Nordisk posted 14.6% weight loss at ADA 2026, with Phase 3 for type 2 diabetes launching now.
Survodutide's Phase 3 Data Hit the NEJM. The Weight Loss Number Isn't the Lead.
The dual GLP-1/glucagon agonist posted 16.6% weight loss in its NEJM Phase 3 — and the visceral fat numbers are the stranger story.
Semax Got the July FDA Vote. Selank Didn't. TikTok Is Selling Both.
The nootropic peptide stack the internet treats as interchangeable just got split by the FDA's advisory panel — and the left-out half has a more complicated story than the marketing admits.
Pemvidutide Just Entered Phase 3. The Alcohol Data From July Is the Story.
The GLP-1/glucagon dual agonist from Altimmune is now in registrational MASH trials — and the July alcohol use disorder data raises a question the obesity pipeline has not had to answer before.
CJC-1295 Is Half of Every GH Stack. The April 2026 FDA List Left It Off.
The most-prescribed GH axis stack survived the 2026 FDA reclassification — but only one half made the April list.
PT-141 Is TikTok's Sex Peptide. The Approved Label Tells a Different Story.
The peptide going viral as a libido booster is FDA-approved — for a specific diagnosed condition in premenopausal women that most of the people posting about it don't have.
WADA Banned AOD-9604 in 2026. Its Own Fat-Loss Trial Said Otherwise.
The GH fragment peptide made WADA's 2026 Prohibited List and lost its FDA compounding pathway this year — 19 years after the drug company that invented it quietly walked away.
Cagrilintide Couldn't Beat Tirzepatide in a Head-to-Head. The FDA Still Has a Q4 Decision to Make.
Novo Nordisk's amylin analog posted 23% weight loss against tirzepatide in 2026 — and missed the noninferiority threshold. The FDA verdict is expected this quarter.
Thymosin Alpha-1 Is Back. The Phase 3 Sepsis Trial Wants a Word.
The immune peptide approved in 35 countries just returned to U.S. compounding clinics — and the most rigorous trial ever run on it quietly missed its primary endpoint.
TikTok's Barbie Drug Is a Melanocortin Peptide. The Approved One Does Something Completely Different.
The illegal tanning shot flooding TikTok this month uses the same receptor system as an FDA-approved obesity drug — and the two could not be more different.
TB-500 Got Its FDA Panel Vote. The Evidence File Had No Human Data.
The same July session that covered BPC-157 also voted on TB-500 — for wound healing — while FDA staff reported zero direct human administration studies for the peptide.
The PCAC Just Voted Yes on Epithalon. Most of the Studies Were About a Completely Different Substance.
A July PCAC vote backed the longevity peptide 7-4 — for insomnia, not anti-aging — while FDA staff said most supporting studies tested a different substance.
Semax Got the FDA Vote in July. The Nootropic Internet Has a Different Agenda.
The PCAC recommended semax for compounding pharmacies last month — for stroke and migraine. The nootropic community heard something else entirely.
The FDA Panel Voted Yes on MOTS-c. The Agency's Own Scientists Voted No.
The late-July PCAC vote backed MOTS-c for compounding over FDA career scientists' objections — while WADA has had it banned as a performance drug for years.
Sermorelin Was the Safe GH Peptide. The FDA Added a Paperwork Wall in January.
The January 2026 FDA guidance on compounded sermorelin didn't ban it — it added a documentation requirement that changed who can actually get it.
A Pro Ultrarunner Said BPC-157 Fixed His Back. WADA Says It's Banned.
Mike McKnight went public about using a prohibited peptide to avoid back surgery — and right on cue, an FDA advisory panel voted to expand access while the agency's own scientists objected.
200 Lawsuits Claim Ozempic Is Causing Blindness. The FDA Label Hasn't Changed.
A federal MDL for semaglutide vision-loss claims hit 200 cases in August 2026 — and Ozempic's label still carries no NAION warning.
Liraglutide Made the FDA's Compounding Crackdown List. It Already Has a Generic on Pharmacy Shelves.
The FDA grouped liraglutide with Ozempic and Mounjaro in its April 2026 proposal to end 503B bulk compounding — the one drug in the group that already had an authorized generic available.
Ipamorelin Cleared the FDA Concern List in June. The July Panel Moved On Without It.
Ipamorelin got off the FDA safety concern list in June — and the July compounding panel moved right past it. Here's what the regulatory and evidence picture looks like now.
SS-31 Got an FDA Drug Name Last September. The Longevity Community Is Just Catching Up.
Elamipretide became the first FDA-approved mitochondria-targeted therapeutic 11 months ago — for a disease most biohackers don't have.
Every Peptide Got Its FDA Panel Vote in July. GHK-Cu Is the One Still Waiting.
The July 2026 FDA compounding panel cleared six peptides and left out GHK-Cu — the one that simultaneously lives in Sephora and in regulatory limbo.
Kisspeptin Is Having a Moment. The Clinical Trials Point Somewhere Unexpected.
Kisspeptin runs the entire reproductive hormone cascade — the JAMA trials showed its most surprising effect has nothing to do with hormone levels.
Wellness Clinics Found the GH Peptide With Actual FDA Approval. The Prescription Is for Something Else.
The only FDA-approved GHRH analog has had its label for 15 years — wellness clinics are now writing it for something else entirely.
Lilly Sued Six Companies Selling Retatrutide This Week. People Are Still Injecting It.
Retatrutide's Phase 3 data was good enough to generate a black market before FDA approval — and as of August 12, six lawsuits.
TikTok's Illegal Tanning Shot Has an FDA-Approved Version. That's Where the Similarity Ends.
The "Barbie peptide" trend and the FDA-approved melanocortin drug share a receptor. They share nothing else — not an approval, not a safety record, not a legitimate indication.
GLP-1 Drugs Turn Hunger Neurons On. Yale's New Study Just Rewrote the Mechanism.
A PNAS study published this week found that GLP-1 receptor agonists work by activating hunger neurons — not suppressing them — overturning the standard explanation for Ozempic's effects.
The FDA Closed Its Compounded Tirzepatide Comment Window. The Drug's 4-Year Heart Trial Is the Part Neither Side Is Citing.
The comment period on permanently banning bulk-compounded tirzepatide just closed — and the approved drug's clinical case has never been stronger.
IGF-1 LR3 Is Having a Moment. Here's the Part TikTok Isn't Telling You.
The muscle-growth peptide flooding fitness TikTok this month has a real biological mechanism — and essentially no human clinical trials behind it.
The INSULIN Act Passed Committee This Week. The Peptide Behind the Bill Is Stranger Than the Politics.
A bipartisan Senate bill would cap insulin at $35 a month — the peptide at the center just got its biggest engineering milestone in decades.
GIP Is the Hormone in Tirzepatide That Scientists Can't Stop Arguing About.
A Nature Metabolism study published last month explains why both blocking and activating GIP cause weight loss — through entirely different parts of the brain.
Orexin-A Just Became the Most Important Neuropeptide Nobody Was Watching. The FDA Made It Happen.
This week's FDA approval of the first orexin receptor agonist for narcolepsy type 1 is really a story about a neuropeptide your hypothalamus makes — and what happens when the cells that produce it are gone.
Survodutide Lost a Quarter of Its Patients to Side Effects. Three Weeks Later, Boehringer Announced a Replacement.
The new GLP-1 challenger posted the best liver fat numbers in the game. It also had the worst dropout rate.
Semax Got the FDA Vote. Selank Is the Companion Peptide the Panel Skipped.
Russia approved selank for generalized anxiety disorder two decades ago. The FDA hasn't reviewed it once — semax just cleared a committee vote.
Pemvidutide's Phase 3 Just Started. The Lean Mass Story Is Why People Are Watching.
Altimmune launched the PERFORMA liver disease trial on August 3 — but the wellness community got interested months ago, over a body-composition number from 50 people.
Novo Enrolled 1,150 People in an Amycretin Trial. The Dual-Hormone Bet Behind It.
Novo's dual GLP-1/amylin pill outperformed Wegovy in Phase 1 and just entered its biggest human trial yet.
AOD-9604 Is the Fat-Loss Peptide That Failed Its Trial. TikTok Didn't Get the Memo.
While six other peptides earned FDA advisory panel backing this month, AOD-9604's nomination was already withdrawn — and its pivotal efficacy trial never separated from placebo.
CJC-1295 Is Everywhere. Last Week's FDA Panel Left It Off the List.
The peptide anchoring half the GH stacks online didn't make the FDA's July docket — and the safety file tells a specific story.
The FDA Panel Voted Yes on KPV Last Week. The Human Trials Did Not.
Last week, a federal advisory committee backed the anti-inflammatory tripeptide KPV for compounding access — overruling FDA staff who found zero human studies in its evidence file.
PT-141 Is Everywhere. The Legal Version Has a Different Name.
The gray market's most requested libido peptide is already an FDA-approved drug. The gap between those two facts is the real story.
CagriSema Was Supposed to Beat Ozempic. It Came Up Short. Yesterday a Judge Asked Why.
A judge ruled yesterday Novo Nordisk must face fraud claims over CagriSema's weight-loss trial — here's the science behind the gap.
Thymosin Alpha-1 Is a Real Drug in 35 Countries. The FDA Compounding Panel Already Said No.
Thymosin alpha-1 is an approved drug in 35 countries with decades of human data — and the FDA compounding panel already said no.
TB-500 Passed the FDA Panel This Week. The Science Behind the Vote Belongs to a Different Peptide.
The recovery peptide that borrows its entire evidence trail from a different molecule just got an 8-6 compounding pathway vote — for wound healing, not the tendon claims driving market demand.
Semax Cleared the FDA Panel Last Thursday. The Nootropic Claims Weren't Part of the Vote.
An 8-5 FDA advisory panel vote just unlocked the compounding pathway for semax — but not for the cognitive-enhancement claims the internet runs on.
MOTS-c Got the Closest Vote at Wednesday's FDA Panel. Their Scientists Said No.
The mitochondrial peptide that slipped through last week's FDA compounding review by a 7-5 margin has almost no published human trials for the performance claims driving its popularity.
An FDA Panel Just Tightened Sermorelin Rules. Wellness Clinics Are Doing the Math.
An FDA advisory panel voted this week to recommend tighter restrictions on compounded sermorelin — the GH peptide running through wellness clinics with years of market scale and unfinished outcome trials.
The FDA Compounding Panel Just Voted for BPC-157. Read the Dissent First.
The 8-6 FDA advisory vote yesterday opened a compounding pathway for BPC-157 — a peptide with more than 100 animal studies and almost no published human trials for the recovery claims driving its popularity.
Ozempic Might Slow Biological Aging. Last Week's Study Has a Lot of Fine Print.
A Nature Communications paper last week found semaglutide may slow aging — in an HIV population, on one biomarker, with more trials needed.
Biohackers Have Been Injecting Epitalon for Decades. Tomorrow the FDA Reads the File.
The tetrapeptide that biohacking culture turned into a longevity staple is finally in front of an FDA advisory committee — and the human evidence trail is shorter than the origin story.
TikTok's Favorite GH Stack Is Half Legal, Half Banned. The FDA Meets Thursday.
America's most-stacked peptide combo is half-legal right now — and this Thursday's FDA hearing won't fix the other half.
Generic Saxenda Dropped This Week. The GLP-1 Market Has Some Catching Up to Do.
Teva launched the first-ever generic GLP-1 for weight loss on July 18 — and the drug at the center of it spent the last two years being treated as yesterday's news.
Hailey Bieber Loves GHK-Cu. Doctors Have Questions About the 'Copper Uglies.'
The Hollywood Reporter covered the GHK-Cu celebrity injection moment this week. Hailey Bieber is mentioned. So are the copper uglies and gray-market contamination risk.
Every Fertility Researcher Is Flying to Japan Next Week for a Peptide You've Never Heard of.
Kisspeptin controls puberty, adult fertility, and the entire sex hormone axis — and 300 researchers are convening in Nagoya to determine what medicine can actually do with that.
Retatrutide Is Posting 30% Weight Loss Numbers. The Gray Market Found Out First.
Lilly's triple GLP-1/GIP/glucagon agonist just cleared a pivotal Phase 3 obesity trial with numbers that match bariatric surgery — and it's not approved, not at any pharmacy, and already driving a poison-center spike.
TikTok Thinks SS-31 Is a Longevity Hack. The FDA Approved It for 150 Patients.
The compound biohackers call a mitochondria peptide became the first FDA-approved mitochondria drug in September 2025 — for a rare disease affecting about 150 Americans.
GLP-1 Is a Hormone Your Gut Already Makes. Here's What That Actually Means.
As Medicare just opened GLP-1 drugs to millions more Americans, the peptide those drugs imitate is being completely ignored. Meet the original.
Zepbound Is $50 a Month on Medicare Now. Here's the Part Nobody's Saying.
The Medicare GLP-1 Bridge launched July 1 and 40% of U.S. adults qualify — but the coverage architecture has structural quirks the $50 headline buried.
TikTok's Tanning Shot Just Got a Skin Cancer Warning. Here's the Melanocortin Drug the FDA Made.
The Skin Cancer Foundation warned against Melanotan II this week — and the FDA has already approved a melanocortin peptide for a different disease.
Pramlintide Is 20 Years Old. The Amylin Drug Boom Just Made It Interesting Again.
The original FDA-approved amylin analog spent two decades in the clinical margins — then ADA 2026 showed the mechanism works, and the pharma world is now racing to build a better version.
GIP Explains Why Tirzepatide Beats Ozempic. A Paper This Week Changes the Story.
A study published this week engineered a GIP molecule that flips from agonist to antagonist — the weight loss numbers are now a research problem.
Seven Peptides Got an FDA Panel Date This July. IGF-1 LR3 Wasn't Invited.
The April reclassification freed over a dozen peptides and the July FDA review covers seven more — IGF-1 LR3, the most-searched anabolic peptide in bodybuilding, is not in either batch.
KPV Made the FDA's July 23 Docket. The Staff Report Said No First.
The gut and skin peptide KPV gets its FDA committee vote on July 23 — and the pre-meeting staff report recommended against it.
Every GH Peptide on Your Stack Got Legal in April. GHRP-2 Didn't.
The April 2026 peptide reclassification freed ipamorelin, CJC-1295, and a dozen others — and left GHRP-2 behind with the more complete human evidence file.
Amycretin Had the Best Numbers at ADA 2026. Its Semaglutide Head-to-Head Starts in September.
Novo Nordisk's GLP-1 and amylin co-agonist posted 14.6% weight loss in Phase 2b last month — and its direct comparison against semaglutide in obesity is confirmed for fall 2026.
Pemvidutide Is Moving to Phase 3. The Alcohol Data Is What Drops This Month.
A dual GLP-1/glucagon agonist with Breakthrough Therapy Designation for MASH is heading into Phase 3 — and its alcohol use disorder trial results land in Q3 2026.
Selank Searches Are Up 31% Since Spring. The Anxiety Evidence Isn't.
Selank came off the FDA's restricted list this spring, searches climbed 31%, and the anxiety evidence still hasn't caught up.
AOD-9604 Came Off the FDA's Banned List This Spring. The Fat-Loss Claims Didn't Follow.
AOD-9604 returned to compounding-allowed status this spring — and the clinical record that ended its drug-development program is the part the July buzz is skipping.
Every GLP-1 Headline Was About Weight. Survodutide's ADA Data Was About the Liver.
A dual GLP-1/glucagon agonist showed 60% liver fat normalization at ADA 2026 last month — and the clinical data is a different story from every weight headline.
CJC-1295 Came Off the FDA's Banned List in April. The Internet Is Catching Up.
The GH-axis peptide at the center of the optimization stack quietly got its compounding status back this spring — and the clinical evidence didn't change.
The Libido Peptide Everyone Calls PT-141 Has Been an FDA Drug Since 2019. The Gap Is the Story.
PT-141 has been FDA-approved since 2019 as Vyleesi — and the 2026 compounding wave that reshaped peptide access did not change that.
CagriSema Has a New FDA Filing and ADA 2026 Data. The Half That Isn't Semaglutide Does the Explaining.
The amylin analog inside Novo Nordisk's next weight-loss drug just showed up in the NEJM at ADA 2026 — and it's not semaglutide.
TB-500 Made the FDA's July 23 Docket. The Recovery Stack Claims Didn't Make the Evidence List.
TB-500 is on the July 23 FDA compounding docket — and the oral comment window closes in three days with the recovery claims still unproven.
Semax Got a July FDA Hearing Date. The Nootropic Claims Aren't the Agenda.
The ACTH-fragment peptide from Russia just made the FDA's July 24 compounding docket — and the committee is reviewing a pharmacy-access question, not a cognitive-enhancement claim.
MOTS-c Just Made the FDA's July Docket. The 'Exercise Peptide' Frame Has a Problem.
The mitochondrial peptide trending as exercise-in-a-vial just made the FDA's July 23 agenda — but regulators are asking about obesity and osteoporosis, not athletic optimization.
Sermorelin Escaped the 2023 Peptide Purge. FDA Attestation Rules in 2026 Found It Anyway.
Sermorelin survived the 2023 compounding crackdown by not being on the restricted list. In 2026, new FDA attestation rules found it anyway.
Fifty Years of BPC-157 Animal Data Just Got an FDA Hearing Date. The Human Trials Are Still Missing.
STAT News profiled BPC-157's creator this month — the FDA's July 23 review finds five decades of animal data and no human trials.
Compounded Semaglutide Ends This Week. Medicare's Version Starts Next.
The FDA's June 29 deadline ends compounded semaglutide's legal pathway — and nine days later, Medicare opens Wegovy at $50 a month.
Epitalon Got a July FDA Hearing Date. The Committee Is Asking About Sleep, Not Telomeres.
The biohacking peptide that promises telomere extension just made the FDA's July PCAC docket — and the committee is reviewing it for insomnia, not anti-aging.
Ipamorelin Just Got Off the FDA's Banned List. The Evidence Stayed Behind.
Ipamorelin cleared the FDA's compounding restriction in April 2026 — three years after the ban, with fewer human trials than its forum reputation suggests.
GHK-Cu Is All Over Sephora This Month. The Peptide Biology Is Actually Real.
The copper tripeptide driving 2026's beauty boom just cleared the FDA's compounding ban, and the science behind the serum is worth reading.
Saxenda Got a Generic. ENDO 2026 Just Told Us What GLP-1s Actually Do to Exercise.
The original weight-loss GLP-1 just got a generic — and the ENDO 2026 study about exercise levels applies to every drug in this class.
Retatrutide Isn't Approved. A CBS Investigation Just Found 120 Clinics Prescribing It Anyway.
CBS News this week found 120+ clinics prescribing the unapproved triple-agonist — while ADA Phase 3 safety data landed in the Lancet.
Tirzepatide Drops Pounds. A June Trial Just Measured the Muscle Going With Them.
A phase 2 trial in Nature Medicine this week showed 30% of tirzepatide weight loss is lean mass — and the drug that cut that in half had no effect on strength.
TB-500 Got a Research Stack and a July FDA Date. Thymosin Beta-4 Has a Different Evidence Story.
A June 11 research stack and a July FDA hearing both invoke thymosin beta-4 — but its evidence runs to different places than the forum history suggests.
GHRP-6 Is Still Banned by the FDA. Its Entire Peer Group Just Got Out.
Fourteen peptides cleared the FDA's restricted list in February. GHRP-6 did not, and the reason involves the approved growth hormone category.
Thymosin Alpha-1 Is Approved in 35 Countries. The US Keeps Missing the Meeting.
Zadaxin is approved in 35 countries and just appeared in June fertility research — the US compounding vote went the other way in December.
Everyone's Posting the Melanotan Tanning Shot. The FDA-Approved Version Has a Completely Different Job.
A self-injection video went viral this week showing five months of Melanotan-II use — while the approved melanocortin drug just got a quiet FDA win.
Everybody's Tracking GLP-1 Drugs. The Peptide That Started It All Just Had Its Best ADA Week in Years.
Inhaled insulin just got FDA-approved for children, and ADA 2026 pharmacokinetic data this week shows it outperforming lispro on onset.
IGF-1 LR3 Is Everywhere on TikTok. The Human Evidence Is Not.
The bodybuilding peptide with millions of views this month borrows its biology from insulin-family signaling — and has no completed human randomized trial behind the muscle claims.
KPV Just Got Off the FDA's Restricted List. The Gut-Health Case Wasn't Part of It.
The tripeptide cleared the FDA's restricted list in February and earned a July review date — but the committee's question is about wound healing, not IBD.
GLP-1 Just Got Recommended for Type 1 Diabetes. The Hormone Behind Ozempic Is the Part Nobody Explains.
The ADA's 2026 Standards just added GLP-1 therapy to Type 1 diabetes treatment — and the native hormone behind Ozempic finally gets explained.
Tirzepatide Keeps Beating Semaglutide. GIP Is the Part Nobody's Explaining.
A dedicated GIP and GLP-1 mechanisms symposium opens at ADA 2026 this week — here's the biology behind tirzepatide's edge that most explainers skip.
SS-31 Searches Spiked 47% This Month. The First FDA-Approved Mitochondria Drug Has Been Out Since September.
The mitochondria peptide the longevity community has been chasing for years became an FDA-approved drug last September — for an ultra-rare disease affecting roughly 150 people.
The 24% Weight-Loss Drug Just Got a New Name at ADA 2026. The Phase 3 Story Is More Complicated.
Amycretin got an official INN at ADA 2026 this week — and the Phase 3 behind the 24% number that broke the internet is now enrolling.
The FDA Put Semax on the July Docket. Selank Searches Just Spiked 31% Anyway.
Semax earned a formal FDA review date for July — its nootropic twin Selank is absent from both PCAC lists, and monthly searches just hit +31%.
Survodutide's Phase 3 Results Are In. ADA 2026 Opens in Five Days. The Lean Mass Data Is the Real Story.
Survodutide's Phase 3 results landed last month, ADA 2026 opens June 5, and the lean mass finding is why this one isn't just another GLP-1 drug.
CJC-1295 Is Off the Restricted List. The FDA's July Review Went to Everyone Else.
The most prescribed GH peptide in American clinics cleared the FDA's Category 2 ban this spring — and still has no formal review date before July.
Pemvidutide Is Everywhere as the 'Muscle-Safe' GLP-1. The EASL Data Yesterday Is About Your Liver.
Altimmune dropped 48-week liver fibrosis data at EASL 2026 yesterday — and the wellness community was watching for a completely different number.
Melanotan-II Got 27 Fines in Australia. Here's the Part Nobody's Talking About.
Australia's TGA just cracked down on the illegal tanning shot this month — and the melanocortin receptor behind it also produced an FDA-approved medicine with a completely different story.
AOD-9604 Cleared the FDA's Ban List. The Phase 2 Data Didn't Change.
AOD-9604 cleared the FDA's Category 2 restricted list last month — the Phase 2b trial that ended development in 2007 has not changed.
CagriSema Didn't Beat Zepbound. Here's the Muscle Data Nobody's Talking About.
Cagrilintide lost the head-to-head with Zepbound in February. New body composition data from May changes what that means.
MOTS-c Is the Internet's Exercise Peptide. The FDA's July Review Asks About Obesity.
Biohackers call it 'exercise in a pill,' but the July PCAC docket lists MOTS-c for obesity and osteoporosis — not performance.
TB-500 Got the Same FDA Hearing Date as BPC-157. This One Is About Recovery.
TB-500 is on the same July PCAC docket as BPC-157 — and for once, the federal indication actually tracks with the recovery story.
BPC-157 Finally Got a Federal Review Date. The FDA Isn't Asking About Recovery.
The most searched recovery peptide on the internet has its first formal federal review scheduled for July — and the clinical indication the FDA is evaluating is ulcerative colitis, not tendon or tissue repair.
Semaglutide Got a Liver Disease Approval. The EASL Data This Week Changes What That Means.
Nine months after semaglutide became the first GLP-1 approved for a serious liver disease, new data being unveiled at EASL 2026 this week is expanding what that approval actually covers.
Sermorelin Is Suddenly Everywhere. The Reason Andrew Huberman Quit Is More Useful Than the Hype.
The growth hormone peptide that was never banned from compounding is the story this month — and Huberman's experience is the caveat everyone's missing.
Semax Just Got an FDA Review Date. The Case Being Made Is Not About Nootropics.
The peptide everyone in biohacking circles uses for focus just got its first formal U.S. regulatory review — for stroke and migraine, not cognitive enhancement.
Epitalon Just Got an FDA Review Date. The Case Being Made Is Not About Aging.
The longevity community's favorite tetrapeptide is formally scheduled for federal review this summer — and the stated clinical indication is insomnia, not telomere extension.
Ipamorelin Is Having a Moment. Here's the Part Nobody's Saying.
The GH secretagogue everyone wants back already had its FDA advisory committee review — and the 2024 vote wasn't good news.
The FDA Just Moved on GHK-Cu. The Internet Read It Wrong.
The copper peptide trending across TikTok this month got a real regulatory update in April — and the internet's read of it skipped every important detail.
Liraglutide Has a Generic Now. The FDA Just Said That Ends the Compounding Story.
The oldest GLP-1 weight-loss drug just got a generic and a regulatory crackdown in the same year.
Tirzepatide Just Beat Semaglutide in a Mortality Study. Here's the Part Nobody's Saying.
New data from Digestive Disease Week 2026 shows tirzepatide outperforming semaglutide on mortality and GI events — but the study design is doing more work than the headlines let on.
Retatrutide Just Broke the Weight-Loss Record. Then a New Side Effect Appeared.
The triple agonist just posted the strongest Phase 3 numbers in its class — and a skin-sensation side effect nobody predicted.
CJC-1295 vs Ipamorelin: What They Actually Do.
Two GH-axis peptides are often paired online, but they press different biological switches.
Semaglutide Changed Weight Loss. Here's the Biology.
GLP-1 receptor signaling, appetite circuitry, glucose context, and why approved use is different from gray-market imitation.
Research Peptides: The Label That Should Make You Slow Down.
A research label is not a quality seal. It is a signal to ask harder questions about approval, purity, claims, and human use.
TB-500: Recovery Peptide or Internet Myth?
A clean separation between thymosin beta-4 biology, TB-500 claims, and the evidence people actually need.
BPC-157 Is Everywhere. The Human Evidence Is Not.
The recovery peptide people talk about most is still carried by preclinical evidence, regulatory ambiguity, and a lot of extrapolation.